on Sandoz Group AG (isin : CH1243598427)
20 Years of Biosimilar Medicines: Sandoz Celebrates a Milestone
On 13 April 2026, Sandoz Group AG commemorates the 20th anniversary of the European regulatory approval for Omnitrope®, the world’s first biosimilar medicine. Since 2006, Omnitrope has significantly impacted European healthcare systems, offering over 118 million patient treatment days and savings exceeding USD 1.9 billion.
The approval marked a pivotal moment in healthcare, heralding increased competition and wider patient access. Sandoz's CEO, Richard Saynor, highlights a forthcoming 'golden decade' with patent expiries valued at USD 320 billion, potentially transforming healthcare further.
Over two decades, biosimilars have saved EUR 56 billion in healthcare costs and provided nearly seven billion treatment days in Europe. Sandoz remains committed to affordable biologic medicines, boasting a portfolio of 13 biosimilars.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Sandoz Group AG news